Your SlideShare is downloading. ×
0
-CARDIOMYOPATHIES-CLASSIFICATION,ETIOLOGY,TREATMENT                BY        PIJUSH KANTI MANDAL      PGT; GENERAL MEDICIN...
Cardiomyopathies The cardiomyopathies are a group of diseases that primarily effect the heart muscles and are not the res...
CARDIOMYOPATHYCLASSIFICATION Two fundamental forms of cardiomyopathy are  recognised— 1)primary:- consisting of heart mu...
CARDIOMYOPATHYETIOLOGIC CLASSFICATIONPrimary myocardial involvement:-          1.Idiopathic(D,R,H)          2.Familial(D,R...
CARDIOMYOPATHYCLASSIFICATION(contd..)Secondary myocardial involvement:-           Infective(D): viral myocarditis,bacteri...
CARDIOMYOPATHYCLASSFICATION (CONTD..)           Neuromuscular: muscular dystrophy, myotonic            dystrophy,friedric...
Clinical classification of cardiomyopathy  1.Dilated cardiomyopathy:        Left and/or right ventricular enlargement     ...
Dilated cardiomyopathy
DCM About one in three cases of heart failure is due to DCM Left and/or right ventricular systolic pump function is  imp...
DCM
DCM--incidence Prevalence is 36 per 100,000 population Third most common cause of heart failure Most frequent cause of ...
Genetic consideration One-fifth to one third of patients have familial forms  of DCM Mutation in >20 genes,transmitted i...
DCMCLINICAL MENIFESTATION: Highest incidence in middle age    Blacks 2x more frequent than whites    Men 3x more freque...
DCMCLIN. MENF---- Symptoms/Signs of heart failure    Pulmonary congestion (left heart failure)       dyspnea (rest, exer...
DCMDIAGNOSTICS… CXR (enlarged heart, CHF) Electrocardiogram (tachycardia, A-V block, LBBB, NSSTT  changes, PVC’s) 24-ho...
DCMTREATMENT: Majority particularly>50 yrs die within 4years of onset Spontaneous improvent or stabilization in one-quar...
 Initiate standard treatment of HF medical therapy   ACE inhibitors   diuretics   Digoxin   Hydralazine/nitrate comb...
DCMTREATMENT CONTD..• Implantable cardiac defibrilator Cardiac transplantation    This disorder is the most common indic...
Some other forms of DCM ALCOHOLIC CARDIOMYOPATHY:      Individuals who consumes >90g/day of alcohol for many years     ...
 NEUROMUSCULAR DISEASES:    In duchenne’s progressive muscular dystrophy, there is     mutation in gene encoding cardiac...
DCM Drugs :       Adriamycin: systolic dysfunction and ventricular arrhythmia occur        in a dose dependant manner wi...
DCM ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY/DYSPLASIA   Familial cardiomyopathy, autosomal dominant   Progressi...
DCM TAKO-TSUBO CARDIOMYOPATHY:       Also known as apical ballooning syndrome       Patients presents with abrupt onset...
Hypertrophic cardiomyopathy
HCM HCM is characterised by LV hypertrophy,typically of a  non-dilated chember, without any obvious cause like  HTN,AoS....
VARIANTS OF HCM
VARIANTS OF HCM
HCM      •   The major abnormality of the heart in          HCM is an excessive thickening of the          muscle. Thicken...
HCM      •   Asymmetric septal hypertrophy          with obstruction to the outflow of          blood from the heart may o...
HCM Dynamic LV outflow tract obstruction    Outflow tract gradient (>30 mm Hg), considered severe if >50 mm     Hg (occu...
HCM Approximately 30% of patients with HCM have a dynamic  systolic pressure gradient in the left ventricular outflow tra...
HCM Gradient greater than 50 mmHg, the percentage of systolic  volume ejected before the beginning of SAM is greatly redu...
HCMCLINICAL FEATURE : Asymptomatic    Echocardiographic finding only Symptomatic    Dyspnea in 90%    Angina pectoris...
HCM-Diagnostics Abnormal in 85-90% of cases LVH, Strain pattern Abnormal ST-T’s, giant T wave inversions Abnormal Q’s,...
HCM-Diagnostics LVH usually develops between 5-15 years of age in HCM A normal ECHO in a young child does not R/O the di...
HCM-Clinical course Clinical presentation from infancy to old age Variable clinical course 25 % of cohort achieve normal...
HCM Clinical course Risk of SCD higher in children, may be as high as 6% per year,    majority have progressive hypertrop...
HCM--Risk factors for SCD   Young age (<35 years)   “Malignant” family history of sudden death   Aborted sudden cardiac...
HCM-RECOMMENDATION FOR ATHELETS Low-risk older patients (>30 years) may participate in athletic  activity if all of the f...
MANAGEMENT OF HCM Dehydration should be avoided Digitalis, diuretics,dihydropins, vasodilators should be avoided Drug t...
Hypertensive HCM of elderly• Characteristics   – Modest concentric LV hypertrophy (<22 mm)   – Small LV cavity size   – As...
Inherited metabolic cardiomyopathies with LVH Cardiac Danon Disease:             Mutation in x-linked LAMP2.           ...
 Glycogen storage disease:       Mutation in PRKAG2 adenosin monophosphate-activated protein        kinase.ventricular h...
Restrictve cardiomyopathy
RCM• Hallmark: abnormal diastolic function• Rigid ventricular wall with impaired ventricular filling• Bear some functional...
RCM              Classification Idiopathic Myocardial                               Endomyocardial    Noninfiltrative ...
RCMCLINICAL MENIFESTATION:• Symptoms of right and left heart failure• Jugular Venous Pulse elevated• kussmaul’s sign posit...
RCMEXXCLUSION GUIDELINES: LV end-diastolic dimensions  7 cm Myocardial wall thickness 1.7 cm LV end-diastolic volume 15...
Restriction vs. ConstrictionHistory provide can important clues Constrictive pericarditis   history of TB, trauma, peric...
RCMTREATMENT:• No satisfactory medical therapy• Drug therapy must be used with caution   – Diuretics for extremely high fi...
 Eosinophilic endomyocardial disease:           Also called loeffler’s endocarditis           Cardiac damage is apparen...
 Cardiac amyloidosis:           Deposition of amyloid in the myocardium           Uncommon in secondary form          ...
Other restricive cardiomyopathies Iron-overload cardiomyopathy:               Should be suspected inbackground of diabet...
!!!THANK YOU!!!
Upcoming SlideShare
Loading in...5
×

Cardiomyopathiesclassification,oetiology and treatment

1,054

Published on

Published in: Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,054
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
122
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Transcript of "Cardiomyopathiesclassification,oetiology and treatment"

  1. 1. -CARDIOMYOPATHIES-CLASSIFICATION,ETIOLOGY,TREATMENT BY PIJUSH KANTI MANDAL PGT; GENERAL MEDICINEBURDWAN MEDICAL COLLEGE; BURDWAN
  2. 2. Cardiomyopathies The cardiomyopathies are a group of diseases that primarily effect the heart muscles and are not the result of congenital, acquired vulvular, hypertensive, coronary arterial, or pericardial abnormalities. The term cardiomyopathy should be restricted to the conditions which primarily effect the myocardium.
  3. 3. CARDIOMYOPATHYCLASSIFICATION Two fundamental forms of cardiomyopathy are recognised— 1)primary:- consisting of heart muscle disease predominantly involving the myocardium and/or of unknown cause. 2)secondary:-myocardial disease of unknown cause or associated with systemic disease(eg; chronic alcohol use,amyloidosis)
  4. 4. CARDIOMYOPATHYETIOLOGIC CLASSFICATIONPrimary myocardial involvement:- 1.Idiopathic(D,R,H) 2.Familial(D,R,H) 3.Eosinophilic endomyocardial fibrosis(R) 4. Endomyocardial fibrosis(R)
  5. 5. CARDIOMYOPATHYCLASSIFICATION(contd..)Secondary myocardial involvement:-  Infective(D): viral myocarditis,bacterial myocarditis, fungal myocarditis,protozoal, metazoal, rickettsial, spirochetal myocarditis.  Metabolic(D):  Familial storage disease(D,R): glycogen storage disease, mucopolysachcharidosis, hemochromatosis,fabry’s disease  Deficiency(D): elecrolytes,nutrional  Connective tisssue disease: systemic lupus erythematosus,polyarteritis nodosa,rheumatoid arthritis,progressive systemic sclerosis, dermatomyositis  Infiltrations & granulomas(R,D): amyloidosis, sarcoidosis,malignancy
  6. 6. CARDIOMYOPATHYCLASSFICATION (CONTD..)  Neuromuscular: muscular dystrophy, myotonic dystrophy,friedrich’s ataxia(H,D)  Sensitivity & toxic reaction(D): alcohol,drugs,radiation  Peripartum heart disease
  7. 7. Clinical classification of cardiomyopathy 1.Dilated cardiomyopathy: Left and/or right ventricular enlargement Impaired systolic function Congestive cardiac failure Arrhythmias, emboli 2.Restrictve cardiomyopathy: Endomyocardial scarring or myocardial infiltration resulting in restriction to left and/or right ventricular filling 3.Hypertrophic cardiomyopathy: Dysproprtionate left ventricular hypertrophy,typically involving the septum more than the free wall with or without an intraventricular systolic pressure gradiant,ususally of a non dilated ventricular cavity.
  8. 8. Dilated cardiomyopathy
  9. 9. DCM About one in three cases of heart failure is due to DCM Left and/or right ventricular systolic pump function is impaired leading to progressive dilatation Most of the cases are of unknown etiology and is termed as idiopathic DCM Secondary Causes include ischaemia,alcoholic peripartum,post infectious, viral Most common of all cardiomyopathies.
  10. 10. DCM
  11. 11. DCM--incidence Prevalence is 36 per 100,000 population Third most common cause of heart failure Most frequent cause of heart transplantation DCM accounts for approximately 10,000 deaths and 46,000 hospitalizations per year in the US Spontaneous recovery occur in one-quarter of patients
  12. 12. Genetic consideration One-fifth to one third of patients have familial forms of DCM Mutation in >20 genes,transmitted in AD fashion. Most commonly genes encoding Sarcomeric proteins,such as alpha cardiac actin, beta and alpha myosin, heavy chain alpha myosine,troponin T, I &C.
  13. 13. DCMCLINICAL MENIFESTATION: Highest incidence in middle age  Blacks 2x more frequent than whites  Men 3x more frequent than women Symptoms may be gradual in onset Acute presentation  Misdiagnosed as viral URI in young adults  Uncommon to find specific myocardial disease on endomyocardial biopsy
  14. 14. DCMCLIN. MENF---- Symptoms/Signs of heart failure  Pulmonary congestion (left heart failure) dyspnea (rest, exertional, nocturnal), orthopnea  Systemic congestion (right heart failure) edema, nausea, abdominal pain, nocturia  Low cardiac output  Hypotension, tachycardia, tachypnea  Narrow pulse pressure  Elevated JVP  Fatigue and weakness Arrhythmia  Atrial fibrillation, conduction delays, complex PVC’s, sudden death
  15. 15. DCMDIAGNOSTICS… CXR (enlarged heart, CHF) Electrocardiogram (tachycardia, A-V block, LBBB, NSSTT changes, PVC’s) 24-hour Holter monitor  if lightheadedness, palpitation, syncope Echocardiogram,CTI,CMRI(left ventricular dilation,with normal or minimally thickened or,thinned walls, global hypokinesis, low EF) Elevated BNP Cardiac catheterization (R/O CAD) Myocardial biopsy, rare  if age >40, ischemic history, high risk profile, abnormal ECG Myocardial biopsy(rare)
  16. 16. DCMTREATMENT: Majority particularly>50 yrs die within 4years of onset Spontaneous improvent or stabilization in one-quarter Death due to progressive HF,V-tach SCD is a constant threat Systemic embolization is a concern Alcohol should be avoided. As should the CCBs,NSAIDs Avoid antiarrhythmics Salt restriction Fluid restriction
  17. 17.  Initiate standard treatment of HF medical therapy  ACE inhibitors  diuretics  Digoxin  Hydralazine/nitrate combination  Anticoagulation prophylaxis(EF <30%, hx of embolic events)
  18. 18. DCMTREATMENT CONTD..• Implantable cardiac defibrilator Cardiac transplantation  This disorder is the most common indication for cardiac transplantation  Survival after transplant is  80% one year  70% 5 years Left Ventricular Reduction Procedures  LV-reshaping
  19. 19. Some other forms of DCM ALCOHOLIC CARDIOMYOPATHY:  Individuals who consumes >90g/day of alcohol for many years  Clinical picture resembling idiopathic or familial DCM  Partially genetically predetermined (ALDH2)  Abstention may halt the progression or even reverse PERIPARTUM CARDIOMYOPATHY :  Cardiac dilatation with CHF develope during last trimester or within 6 months of delivery.  Typically present in multiparous of age >30 yrs  Unknown cause  Inflammatory myocarditis, immune activation,gestational have been incriminated  Symptoms,signs and management are that of IDCM  Further pregnancy should be discouraged
  20. 20.  NEUROMUSCULAR DISEASES:  In duchenne’s progressive muscular dystrophy, there is mutation in gene encoding cardiac structural protein(dystrophin) lead to myocyte death. • ECG: tall ‘R’ wave in right precordial leads with R/S>1.0,associated with deep Q in limb and lateral precordial leads • Rapidly progressive HF with extended periods of apparent circulatory stability.  In myotonic dystrophy there is disorders of impulse generation and AV conduction. • Evidence of overt heart disease is uncommon • Insertion of ICD or pacemaker is effective.
  21. 21. DCM Drugs :  Adriamycin: systolic dysfunction and ventricular arrhythmia occur in a dose dependant manner with a dose of >450mg/dl  Concomitant cyclphosphamide, irradiation,underlyig HF are the risk factors for cardiotoxicity.  Toxicity may occur acutely but more commonly developes a median of 3 months after last dose  Modification of dose along with the use of ironchelator dexrazoxone have reduced the risk of cardiotoxicity.  ACE inhibitors may cause recovery of cardiac function  Other drugs include  Trustuzumab  High dose cyclophosphamide  Imatinib mesylate  TCA,Lithium , cocaine abuse
  22. 22. DCM ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY/DYSPLASIA  Familial cardiomyopathy, autosomal dominant  Progressive fibrofatty tissue replacement of right ventricle and to a lesser degreee of left ventricular myocardium  Mutation in genes encoding desmosomes,causes detachment in myocytes and consequent apoptosis and replacement with fibrofatty tissue.  PKP2 gene mutation  Ryanodine recepter gene(RyR2) mutation  Patients present with right heart failure  ECG:-QRS prolongation in right precordial leads with LBBB type of VT  CTI,CMRI will show right ventricular dilatation and fibrofatty deposition and aneurysm Restriction from competetive sports, antiarrythmic therapy, with beta blockers &amiodarone Implantation OF ICD Cardiac transplantation
  23. 23. DCM TAKO-TSUBO CARDIOMYOPATHY:  Also known as apical ballooning syndrome  Patients presents with abrupt onset severe chest pain by a very stressfull emotion &physical events  women>50 yrs  ECG:ST ,withT In precordial leads, EF, troponin  ECHO: akinesia of distal portion of left ventricle  CAG: Normal  CTI: ‘Ballooning’ of left ventricle specifically apex in end systole  Reversible within 3-7 days  Beta blockers is of doubtful significance in Rx LEFT VENTRICULAR NON COMPACTION(LVNC):  Arrest of normal embryogenesis with persistance of deep recesses &sinusoides in the myocardiumthat characterise the embryonic heart.  ECHO- Multiple deep trabeculations into the myocardium which communicate with the ventricular cavity causing left ventricular contractile dysfunction  Rx- standard therapy for CHF along with chronic anticoagulation.
  24. 24. Hypertrophic cardiomyopathy
  25. 25. HCM HCM is characterised by LV hypertrophy,typically of a non-dilated chember, without any obvious cause like HTN,AoS. Two features of HCM have attracted most significance  Asymetric hypertrophy of the left ventricle with the preferential hypertrophy of the IVS  A dynamic left ventricular outflow tract pressure gradiant,related to narrowing of the sub aortic area.
  26. 26. VARIANTS OF HCM
  27. 27. VARIANTS OF HCM
  28. 28. HCM • The major abnormality of the heart in HCM is an excessive thickening of the muscle. Thickening usually begins during early adolescence and stops when growth has finished. It is uncommon for thickening to progress after this age • The left ventricle is almost always affected, and in some patients the muscle of the right ventricle also thickens • Hypertrophy is usually greatest in the septum. The muscle thickening in this region may be sufficient to narrow the outflow tract. This thickening is associated with obstruction to the flow of blood out of the heart into the aorta
  29. 29. HCM • Asymmetric septal hypertrophy with obstruction to the outflow of blood from the heart may occur. The mitral valve touches the septum, blocking the outflow tract. Some blood is leaking back through the mitral valve causing mitral regurgitation
  30. 30. HCM Dynamic LV outflow tract obstruction  Outflow tract gradient (>30 mm Hg), considered severe if >50 mm Hg (occurs in 25-30% of cases leading to name hypertrophic obstructive cardiomyopathy) Diastolic dysfunction  Impaired diastolic filling, filling pressure Mitral regurgitation Arrhythmias:SVT,AF,VT
  31. 31. HCM Approximately 30% of patients with HCM have a dynamic systolic pressure gradient in the left ventricular outflow tract caused by contact between the mitral valve leaflet(s) and the interventricular septum under resting conditions Outflow tract gradient in excess of 30 mmHg is an important cause of symptoms Gradient is simply a consequence of high velocity flow through the aortic valve, and hence does not represent a real obstruction to cardiac output .
  32. 32. HCM Gradient greater than 50 mmHg, the percentage of systolic volume ejected before the beginning of SAM is greatly reduced - responsible for patients symptoms.When severe, outflow tract gradient can cause dyspnea, chest pain, syncope, and predisposes to the development of atrial arrhythmias - independent predictor of disease progression and adverse outcome, including sudden death
  33. 33. HCMCLINICAL FEATURE : Asymptomatic  Echocardiographic finding only Symptomatic  Dyspnea in 90%  Angina pectoris in 75%  Fatigue, pre-syncope, syncope, risk of SCD  Palpitation, PND, CHF, dizziness  Atrial fibrillation, thromboembolism
  34. 34. HCM-Diagnostics Abnormal in 85-90% of cases LVH, Strain pattern Abnormal ST-T’s, giant T wave inversions Abnormal Q’s, Bundle Branch Block Left atrial enlargment Ventricular arrhthymias
  35. 35. HCM-Diagnostics LVH usually develops between 5-15 years of age in HCM A normal ECHO in a young child does not R/O the diagnosis Serial ECHOs are recommended up to the age of 20 yr where there is a family history of HCM An unusual form od cardiomyopathy, characterised by apical hypertrophy, is associated withgiant negative T waves and a spade shaped LV cavity; usually of a benign course.
  36. 36. HCM-Clinical course Clinical presentation from infancy to old age Variable clinical course 25 % of cohort achieve normal longevity Annual mortality 3% in referral centers probably closer to 1% for all patients Course may be punctuated by adverse clinical events: sudden cardiac death, embolic stroke, and consequences of heart failure Sustained V-Tach and V-Fib: most likely mechanism of syncope/ sudden death
  37. 37. HCM Clinical course Risk of SCD higher in children, may be as high as 6% per year, majority have progressive hypertrophy Accounts for 36% of deaths in athletes <35 years Clinical deterioration usually is slow Poor prognosis in males, young age of onset, family Hx of SCD, Hx of syncope, exercise induced hypotension (worst) Progression to DCM occurs in 10-15%
  38. 38. HCM--Risk factors for SCD Young age (<35 years) “Malignant” family history of sudden death Aborted sudden cardiac death Sustained VT or SVT Non-sustained VT on holter monitoring Atrial fibrillation Dilated left ventricle NYHA classes III or IV Syncope Severe hypertrophy(>3.0 cm) Abnormal BP response to exercise Coronary artery disease Strenous exercise or work
  39. 39. HCM-RECOMMENDATION FOR ATHELETS Low-risk older patients (>30 years) may participate in athletic activity if all of the following are absent:  Ventricular tachycardia on Holter monitoring  Family history of sudden death due to HCM  History of syncope  Severe hemodynamic abnormalities, gradient 50 mmHg  Exercise induced hypotension  Moderate or severe mitral regurgitation  Enlarged left atrium ( 5.0 cm)  Paroxysmal atrial fibrillation  Abnormal myocardial perfusion
  40. 40. MANAGEMENT OF HCM Dehydration should be avoided Digitalis, diuretics,dihydropins, vasodilators should be avoided Drug therapy Beta-adrenergic blockers Calcium channel blockers (verapamil, diltiazem, etc) disopyramide Anti-arrhythmics – Amiodarone; Pacemakers (ICD) Myomectomy (resection of septum) Alcohol septal ablation (controlled MI through septal perforator perfusing basal septum) wall thinningdecreases in LVOTO Transplantation
  41. 41. Hypertensive HCM of elderly• Characteristics – Modest concentric LV hypertrophy (<22 mm) – Small LV cavity size – Associated hypertension – Ventricular morphology greatly distorted with reduced outflow tract – Sigmoid septum and “grandma SAM” echocardiographic finding only
  42. 42. Inherited metabolic cardiomyopathies with LVH Cardiac Danon Disease:  Mutation in x-linked LAMP2.  Enlarged ventricular myocytes with PAS positive inclusions.  Presents in chilhhood with serious arrhythmias  ECG:LVH ventricular preexcitation• Friedrich’s Ataxia:  Degenerative disease caused by inadequate levels of frataxin,a protein involved in mitochondrial iron metabolism.  Echo,CTI,CMRI shows symetric LVH with asymetric IVS hypertrophy  Lacks cellualar disarray as of HCM
  43. 43.  Glycogen storage disease:  Mutation in PRKAG2 adenosin monophosphate-activated protein kinase.ventricular hypertrophy resembling HCM and enlarged myocytes with vacoules in the myocytes that stain for glycogen• Fabry Disease:  X-linked autosomal recessive lysosomal disorder caused by deficiency of lysosomal alpha galactosidase A, leading to accumulation of glycosphingolipids in the heart leading to ventricular hypertrophy.  Because of severe impairment in ventricular filling, it is sometimes classified as a restrictive cardiomyopathy  Treatment consists of enzyme replacement therapy with agalsidase Beta
  44. 44. Restrictve cardiomyopathy
  45. 45. RCM• Hallmark: abnormal diastolic function• Rigid ventricular wall with impaired ventricular filling• Bear some functional resemblance to constrictive pericarditis• Importance lies in its differentiation from operable constrictive pericarditis• Much less common then DCM or HCM outside the tropics, but frequent cause of death in Africa, India, South and Central America and Asia primarily because of the high incidence of endomyocardial fibrosis in those regions
  46. 46. RCM Classification Idiopathic Myocardial  Endomyocardial  Noninfiltrative  Idopathic  Endomyocardial fibrosis  Scleroderma  Hyperesinophilic synd  Infiltrative  Carcinoid  Amyloid  Sarcoid  Metastatic malignancies  Gaucher disease  Radiation, anthracycline  Hurler disease  Storage Disease  Hemochromatosis  Fabry disease  Glycogen storage
  47. 47. RCMCLINICAL MENIFESTATION:• Symptoms of right and left heart failure• Jugular Venous Pulse elevated• kussmaul’s sign positive• Echo-Doppler – Abnormal mitral inflow pattern – Symetrically thickend LV walls and systolic dysfunction – Prominent E wave (rapid diastolic filling) – Reduced deceleration time ( LA pressure)
  48. 48. RCMEXXCLUSION GUIDELINES: LV end-diastolic dimensions 7 cm Myocardial wall thickness 1.7 cm LV end-diastolic volume 150 mL/m2 LV ejection fraction < 20%
  49. 49. Restriction vs. ConstrictionHistory provide can important clues Constrictive pericarditis  history of TB, trauma, pericarditis, collagen vascular disorders Restrictive cardiomyopathy  amyloidosis, hemochromatosis Mixed  mediastinal radiation, cardiac surgery
  50. 50. RCMTREATMENT:• No satisfactory medical therapy• Drug therapy must be used with caution – Diuretics for extremely high filling pressures – Chronic anticoagulation is often recommended – Vasodilators may decrease filling pressure – (?) Calcium channel blockers to improve diastolic compliance – Digitalis and other inotropic agents are not indicated
  51. 51.  Eosinophilic endomyocardial disease:  Also called loeffler’s endocarditis  Cardiac damage is apparent result of toxic effect of eosinophilic proteins  Endocardium of both ventricles enlarged  Imaging reveals ventricular thickening of the postero basal LV wall.  Management is with diuretics,venodilators, anticoagulants  Glucocorticoids, hydroxurea improves survival  Surgical resection of fibrotic tissue
  52. 52.  Cardiac amyloidosis:  Deposition of amyloid in the myocardium  Uncommon in secondary form  Diastolic dysfunction, systolic dysfunction, arrhythmias, orthostatic hypotension  2D ECHO: thickened myocardial wall with a diffuse,hyperrefractile “speckled”appearance  Alkylating agent such as melphalan alng with glucocorticods appears to improove survival  Heart transplantation along with bone marrow or liver kidney transplantation may help in selected patients
  53. 53. Other restricive cardiomyopathies Iron-overload cardiomyopathy:  Should be suspected inbackground of diabetes cirrhosis and skin pigmentation  Diagnosis confirmed by endomyocardial biopsy  Phlebotomy  Continuos subcutaneous use of iron chelators Carcinoid syndrome  The carcinoid syndrome results in endocardial fibrosis ususally of right side.  Stenosis/regurgitation of pulmonary, tricuspid valve.  Similar lesions has been found in fenfluramine phenteramine use• Sarcoidosis:  Associated witA-V block  RV overload with pulmonary hypertension  High degree AV block with other systemic menifestation  Treated with empirical glucocortocoids
  54. 54. !!!THANK YOU!!!
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×